Skip to main content
CRMD
NASDAQ Life Sciences

CorMedix Appoints Ernst & Young as New Auditor Amidst Existing Internal Control Weakness

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$7.51
Mkt Cap
$615.847M
52W Low
$6.125
52W High
$14.96
52W Position info
23% above low
Off High info
50% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

CRMD sits 23% above its 52-week low of $6.125.

Summary

CorMedix Inc. has appointed Ernst & Young LLP as its new independent registered public accounting firm, replacing CBIZ CPAs P.C., with no reported disagreements with the outgoing firm despite a previously disclosed material weakness in internal controls.


Key Events · Corporate Governance and Compliance · CRMD

  • Auditor Dismissal

    CorMedix dismissed CBIZ CPAs P.C. as its independent registered public accounting firm on June 25, 2026.

  • No Disagreements Reported

    The company stated there were no disagreements with CBIZ CPAs on accounting principles, financial disclosure, or auditing scope.

  • Material Weakness Acknowledged

    The dismissal occurred while a previously disclosed material weakness in internal control over financial reporting, related to reviewing significant non-routine transactions, remains.

  • New Auditor Appointed

    Ernst & Young LLP (EY) has been appointed as the new independent registered public accounting firm for the fiscal year ending December 31, 2026.


Analysis · CRMD · Life Sciences

This 8-K reports a change in CorMedix's independent auditor. While the company explicitly stated there were no disagreements with the outgoing firm, CBIZ CPAs, the change occurs in the context of a previously disclosed material weakness in internal controls. The appointment of Ernst & Young, a major accounting firm, could be seen as a step towards addressing these control issues and enhancing audit quality, but the underlying weakness remains a point of attention.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRMD was trading at $7.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $615.8M. The 52-week trading range was $6.13 to $14.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRMD - Latest Insights

CRMD
Nov 16, 2026, 7:30 AM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $4.61
Real-time Price: $4.76 info
Change: +$0.150 (+3%) info
Market Cap: $371.441M info
CRMD
Nov 12, 2026, 8:21 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.15
Real-time Price: $4.76 info
Change: -$0.390 (-8%) info
Market Cap: $371.441M info
CRMD
Nov 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.25
Real-time Price: $4.76 info
Change: -$0.490 (-9%) info
Market Cap: $371.441M info
CRMD
Nov 12, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.25
Real-time Price: $4.76 info
Change: -$0.490 (-9%) info
Market Cap: $371.441M info
CRMD
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.50
Real-time Price: $4.76 info
Change: -$0.740 (-13%) info
Market Cap: $371.441M info